Price, DavidHenley, WilliamDelfini Cançado, José EduardoFabbri, Leonardo MKerstjens, Huib AMPapi, AlbertoRoche, NicolasŞen, ElifSingh, DaveVogelmeier, Claus FNudo, ElenaCarter, VictoriaSkinner, DerekVella, RebeccaSoriano, Joan BKots, MaximGeorges, George2024-01-222024-01-222024-01-20Price, D, Henley, W, Delfini Cançado, J E, Fabbri, L M, Kerstjens, H AM, Papi, A, Roche, N, Şen, E, Singh, D, Vogelmeier, C F, Nudo, E, Carter, V, Skinner, D, Vella, R, Soriano, J B, Kots, M & Georges, G 2024, 'Risk of pneumonia in patients with COPD initiating fixed dose inhaled corticosteroid (ICS) / long-acting bronchodilator (LABD) formulations containing extrafine beclometasone dipropionate versus patients initiating LABD without ICS', Pragmatic and Observational Research, vol. 15, pp. 1-16. https://doi.org/10.2147/POR.S4380311179-7266https://hdl.handle.net/2164/22609Professor Dave Singh is supported by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC). Jaco Voorham is acknowledged for his contribution to protocol development. We would also like to acknowledge Ms. Shilpa Suresh (MSc) of the Observational and Pragmatic Research Institute (OPRI), Singapore, for editorial and formatting assistance which supported the development of this publication. This study was conducted by the Observational and Pragmatic Research Institute (OPRI) Pte Ltd and was funded by Chiesi Farmaceutici S.p.A.165887981enginhaled corticosteroidspneumoniaCOPDextrafine beclometasonelong-acting bronchodilatorsR MedicineNational Institute for Health Research (NIHR)RJournal article10.2147/POR.S43803115